Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 684 clinical trials
Phase 1 First Time in Human (FTIH) Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.

neutrophil count
EGFR
measurable disease
solid tumor
gilbert's syndrome
  • 162 views
  • 22 Sep, 2021
  • 9 locations
A Study of CC-95251 a Monoclonal Antibody Directed Against SIRP in Subjects With Advanced Solid and Hematologic Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

solid neoplasm
cancer treatment
monoclonal antibodies
measurable disease
cetuximab
  • 101 views
  • 31 Oct, 2021
  • 42 locations
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. This study will be used to define the recommended Phase 2 dose (RP2D). The …

measurable disease
solid neoplasm
primary cancer
  • 0 views
  • 03 Dec, 2021
  • 9 locations
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

primary cancer
  • 0 views
  • 01 Aug, 2021
  • 35 locations
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

solid neoplasm
sarcoma
measurable disease
cyclophosphamide
anthracyclines
  • 4 views
  • 27 Nov, 2021
  • 36 locations
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

First in human, open-label, sequential dose escalation and expansion study of oral BAL101553 in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma or high-grade glioma.

solid neoplasm
measurable disease
ovarian cancer
solid tumor
glioblastoma multiforme
  • 0 views
  • 26 Dec, 2021
  • 19 locations
An Open-label Dose Escalation Study to Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).

EGFR
lymphoma
solid tumor
BRAF
TP53
  • 12 views
  • 27 May, 2021
  • 19 locations
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer

It is a non-randomized, multicentric, cohort study, combined with a biological sample collection, a clinical data collection and with a genetic and immunologic biomarkers study. The ProfiLER program aims to implement a personalized cancer medicine approach by proposing to establish the genetic and immunologic profile of the tumor for patients …

advanced cancer
primary cancer
x-rays
  • 12 views
  • 16 Aug, 2021
  • 8 locations
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

This study has dose escalation (Part A, B, C) and dose expansion (Cohorts A-L) parts. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Parts A and B) and in combination with pembrolizumab (Part C). Dose expansion is to evaluate the objective response rate …

paclitaxel
EGFR
metastatic malignant solid tumor
x-rays
solid tumor
  • 177 views
  • 20 Nov, 2021
  • 28 locations
Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study

The primary purpose of this proposed 5-year hybrid effectiveness and implementation study is to evaluate the relative benefit from, and implementation of an Alberta wide clinic-to-community-based cancer and exercise model of care - the Alberta Cancer Exercise (ACE) Program. The investigators hypothesize that the strategy will improve the physical well-being …

primary cancer
cancer treatment
  • 16 views
  • 06 Sep, 2021
  • 2 locations